profit from every $100 of sales.
$0$100
Nephros
$3.05-7.85% today
-31.0% in 1 year
1-year low $2.781-year high $5.79
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $27.77 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nephros sold, what it kept, and what it did with the cash.
Sales went from $9.98 million in 2022 to $18.8 million in 2025, with $1.19 million of profit last year.
SalesProfit
Nephros vs. similar companies
Nephros grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nephros | 27.8× · Fair price | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Nephros's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10 | 14 | 14 | 19 | |
| 5 | 8 | 9 | 12 | |
| -4 | -2 | 0 | 1 | |
| -4 | -1 | 0 | 1 | |
| -7 | -2 | 0 | 1 | |
| -0.70 | -0.15 | 0.01 | 0.11 | |
| 47.4% | 59.0% | 61.6% | 61.9% | |
| -43.5% | -11.2% | 0.0% | 6.1% | |
| -74.0% | -11.1% | 0.5% | 6.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 11 | 12 | 11 | 14 |
| Cash | 4 | 4 | 4 | 5 |
| Total debt | 1 | 2 | 1 | 1 |
| Total liabilities | 2 | 4 | 3 | 3 |
| 6 | 8 | 9 | 10 | |
| 10 | 10 | 11 | 11 | |
| -50.3% | -12.2% | 0.7% | 8.5% | |
| -132.0% | -18.8% | 0.9% | 11.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3 | 1 | -0 | 2 | |
| 0 | 0 | 0 | – | |
| -3 | 1 | -1 | 2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 0 | 0 |
Valuation
- 27.8×
- 50.8×
- –
- 3.6×
- 1.8×
- 20.2×
- 21.4×
- 5.0%
- 3.6%
- 0.0%
Profitability
- 61.9%
- 6.1%
- 6.4%
- 4.3%
- 5.7%
- -29.4%
- 7.7%
- 5.6%
- 6.0%
- 7.3%
Growth
- +23.5%
- –
- +400.7%
- –
- +1.5%
Financial health
- -3.7×
- 0.09
- 7.0%
- 677.0×
- 4.55
- 3.12
- 1.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 47%of 946
Bottom 43%of 872
Top 48%of 565
Top 25%of 867
Top 21%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.01 | 0.01 | +0.0% |
| Mar 12, 2026 | 0.01 | 0.01 | +0.0% |
| Nov 6, 2025 | 0.03 | 0.01 | +200.0% |
| Aug 7, 2025 | 0.02 | -0.03 | +180.0% |
| May 15, 2025 | 0.05 | 0.01 | +400.0% |
| Mar 24, 2025 | 0.03 | -0.01 | +400.0% |
| Nov 7, 2024 | 0.02 | 0.01 | +199.9% |
| Aug 8, 2024 | -0.03 | -0.02 | −100.0% |
News
Nephros GAAP EPS of $0.05 beats by $0.03, revenue of $5.6M beats by $0.11MSeeking Alpha · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
39No pass
Philip Fisher
57No pass
Peter Lynch
81Pass
Joel Greenblatt
11No pass
Charlie Munger
44No pass
Terry Smith
50No pass
Questions about Nephros
Is Nephros a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nephros AI analysis
What does Nephros do?
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It is in Medical - Instruments & Supplies.
Does Nephros pay a dividend?
No. Nephros does not pay a dividend at the moment.
Is Nephros stock halal?
Yes. Nephros passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Nephros stock done over the past year?
Down 31.0% over the past twelve months, to $3.05. It traded between $2.78 and $5.79 and is 47.3% below its high.
Who are Nephros's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Nephros's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.